Not Yet RecruitingPhase 1

A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults

196 participantsStarted 2026-06-24

Plain-language summary

The current clinical study will evaluate the GVGH Quadrivalent Pan-Salmonella vaccine for the first time in healthy adults in Africa. The purpose of the current Phase 1 study is to evaluate the safety, reactogenicity, and the immune response induced by the Pan-Salmonella vaccine.

Who can participate

Age range

18 Years – 45 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Participants who, in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g., completion of the Diary cards, return for follow-up visits).
. Written informed consent obtained from the participant prior to performance of any study specific procedure.
. Healthy participants as established by medical history, clinical examination, and laboratory assessment\*.
. A male or female between and including 18 to 45 years of age at the time of the first study intervention administration, and no older than 45 years of age at second dose administration.
. Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy, or menopause.
. Participants of childbearing potential may be enrolled in the study if the participant:
. Negative HLA-B27 testing.
. Body mass index of 18\>= to \<=30 kg/m2 at Screening.

Exclusion criteria

. Known exposure to S. Typhi, S. Paratyphi A, and non-typhoidal Salmonella confirmed by blood culture during the period starting 3 years prior to first study intervention administration as confirmed using medical history.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of participants with solicited administration site events

Timeframe: From Day 1 to Day 7

Number of participants with solicited administration site events

Timeframe: From Day 61 to Day 67

Number of participants with solicited administration site events

Timeframe: From Day 181 to Day 187

Number of participants with solicited systemic events

Timeframe: From Day 1 to Day 7

Number of participants with solicited systemic events

Timeframe: From Day 61 to Day 67

Number of participants with solicited systemic events

Timeframe: From Day 181 to Day 187

Number of participants with unsolicited events

Timeframe: From Day 1 to Day 30

Trial details

NCT IDNCT07663032

SponsorGlaxoSmithKline

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-11-14

Contact for this trial

US GSK Clinical Trials Call Center

877-379-3718 GSKClinicalSupportHD@gsk.com

View on ClinicalTrials.gov More Salmonella Infections trials

Who can participate

Age range

18 Years – 45 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Participants who, in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g., completion of the Diary cards, return for follow-up visits).
. Written informed consent obtained from the participant prior to performance of any study specific procedure.
. Healthy participants as established by medical history, clinical examination, and laboratory assessment\*.
. A male or female between and including 18 to 45 years of age at the time of the first study intervention administration, and no older than 45 years of age at second dose administration.
. Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy, or menopause.
. Participants of childbearing potential may be enrolled in the study if the participant:
. Negative HLA-B27 testing.
. Body mass index of 18\>= to \<=30 kg/m2 at Screening.

Exclusion criteria

. Known exposure to S. Typhi, S. Paratyphi A, and non-typhoidal Salmonella confirmed by blood culture during the period starting 3 years prior to first study intervention administration as confirmed using medical history.

What they're measuring

Number of participants with solicited administration site events

Timeframe: From Day 1 to Day 7

Number of participants with solicited administration site events

Timeframe: From Day 61 to Day 67

Number of participants with solicited administration site events

Timeframe: From Day 181 to Day 187

Number of participants with solicited systemic events

Timeframe: From Day 1 to Day 7

Number of participants with solicited systemic events

Timeframe: From Day 61 to Day 67

Number of participants with solicited systemic events

Timeframe: From Day 181 to Day 187

Number of participants with unsolicited events

Timeframe: From Day 1 to Day 30